Using AI to identify digital biomarkers for type 2 diabetes
Delivering Evidence Based Care Using Artificial Intelligence to Patients With Diabetes and CardioVascular Comorbidities: The DECIDE-CV Innovation Project
This study is trying to see if a smartwatch can help find new signs of type 2 diabetes by collecting data from people with and without the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 126 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Trial ID | NCT05482958 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify digital biomarkers associated with type 2 diabetes mellitus (T2DM) by integrating sensor data from a wrist-worn wearable device with clinical data. Patients with and without diabetes will be recruited from cardio-metabolic clinics at the McGill University Health Centre. Participants will wear a HOP Technologies watch during two observation periods, allowing for the collection of both passive sensor data and active self-assessments. Machine learning techniques will be employed to analyze the data and establish associations with clinical measures of T2DM.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been diagnosed with type 2 diabetes or have an HbA1c level of 6.5% or higher.
Not a fit: Patients who do not have type 2 diabetes or an HbA1c level below 6.5% may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved identification and management of type 2 diabetes through the use of digital biomarkers.
How similar studies have performed: Other studies utilizing wearable technology and AI for diabetes management have shown promising results, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \> 18 years 2. Able to follow-up with study protocol schedule 3. Life expectancy \> 1 year 4. Case group only a. HbA1c \>= 6.5% or is diagnosed with T2DM Exclusion Criteria: 1. Age \> 18 years 2. Able to follow-up with study protocol schedule 3. Life expectancy \> 1 year 4. Case group only a. HbA1c \>= 6.5% or is diagnosed with T2DM
Where this trial is running
Montreal, Quebec
- McGill University health Center — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Abhinav Sharma — McGill University Health Centre/Research Institute of the McGill University Health Centre
- Study coordinator: Abhinav Sharma, MD
- Email: abhinav.sharma@mcgill.ca
- Phone: 5149341934
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.